DV-Pharm Limited

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 07034936

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		19,021		23,776
Tangible Assets	5		10,726		11,146

			29,747		34,922
CURRENT ASSETS
Stocks	6	87,000		85,250
Debtors	7	395,724		429,021
Cash at bank and in hand		197,710		177,369

		680,434		691,640
Creditors: Amounts Falling Due Within One Year	8	(185,627 )		(201,957 )

NET CURRENT ASSETS (LIABILITIES)			494,807		489,683

TOTAL ASSETS LESS CURRENT LIABILITIES			524,554		524,605

PROVISIONS FOR LIABILITIES
Deferred Taxation			(2,039 )		(2,118 )

NET ASSETS			522,515		522,487

CAPITAL AND RESERVES
Called up share capital	10		521,624		521,624
Profit and Loss Account			891		863

SHAREHOLDERS' FUNDS			522,515		522,487

Page 1

Page 2

DV-Pharm Limited

Balance Sheet (continued)

As At 31 December 2025

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Dipak Mehta

Director

28/08/2026

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

DV-Pharm Limited is a private company, limited by shares, incorporated in England & Wales, registered number 07034936 . The registered office is Devonshire House, 582 Honeypot Lane, Stanmore, Middlesex, HA7 1JS.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to the profit and loss account over its estimated economic life of 20 years.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold	in accordance with the property
Plant & Machinery	15% on reducing balance
Fixtures & Fittings	15% on reducing balance
Computer Equipment	15% on reducing balance

2.5. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

2.6. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

...CONTINUED

Page 3

Page 4

DV-Pharm Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2025

2.6. Taxation - continued

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 12 (2024: 11)

4. Intangible Assets

	Goodwill
	£
Cost
As at 1 January 2025	95,110

As at 31 December 2025	95,110

Amortisation
As at 1 January 2025	71,334
Provided during the period	4,755

As at 31 December 2025	76,089

Net Book Value
As at 31 December 2025	19,021

As at 1 January 2025	23,776

5. Tangible Assets

	Land & Buildings	Plant & Machinery etc.	Total
	£	£	£
Cost
As at 1 January 2025	9,702	52,417	62,119
Additions	-	1,574	1,574

As at 31 December 2025	9,702	53,991	63,693

Depreciation
As at 1 January 2025	6,817	44,156	50,973
Provided during the period	577	1,417	1,994

As at 31 December 2025	7,394	45,573	52,967

Net Book Value
As at 31 December 2025	2,308	8,418	10,726

As at 1 January 2025	2,885	8,261	11,146

Page 4

Page 5

DV-Pharm Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2025

6. Stocks

	2025	2024
	£	£
Finished goods	87,000	85,250

7. Debtors

	2025	2024
	£	£
Due within one year
Other debtors	381,361	414,658
Due after more than one year
Other debtors	14,363	14,363

	395,724	429,021

8. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	103,334	107,965
Other creditors	52,352	65,297
Taxation and social security	29,941	28,695

	185,627	201,957

9. Provisions for Liabilities


	Deferred Tax	Total
	£	£
As at 1 January 2025	2,118	2,118
Deferred taxation	(79 )	(79 )

Balance at 31 December 2025	2,039	2,039

11. Directors Advances, Credits and Guarantees

As at 31 December 2025, DV-Pharm Ltd owed £46,298 to its directors. This amount is reflected accordingly in their respective director's loan account in credit balances, which is shown under Creditors due within one year. Please be advised that the directors have agreed to provide this loan on an interest free basis and the loan is payable on demand.

12. Related Party Transactions

During the year ended 31 December 2025, DV-Pharm Ltd provided a short-term loan of £320,000 to a related company on an interest free basis and the loan is repayable on demand. This loan amount is shown as Other Debtors under Debtors due within one year.

Page 5